• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The vaccine consists of inactivated micro-organisms of certain strains of Lactobacterium acidophilum (which have been deposited in a culture collection) in a physiologically tolerated solution. The micro-organisms, preferably of eight strains, are present in approximately equal numbers per strain; they are obtained by aerobic culture. The vaccine produces immunity and may be used for the therapeutic treatment of the Trichomonas syndrome.
    公开号:SU997599A3
    申请号:SU782699947
    申请日:1978-12-22
    公开日:1983-02-15
    发明作者:Стойкович Любинко
    申请人:Золько Базель Аг (Фирма)；
    IPC主号:
    专利说明:

    (54) METHOD FOR OBTAINING HETEROVACINE FOR TREATING THE SYNDROME OF TRICHOMONADE
    one
    The invention relates to medicine. And relates to a method for the preparation of a "sterilized vaccine" for the treatment of trichomonas syndrome.
    A known method for producing a hetero vaccine consists in growing cultures of microorganisms (pertussis, diphtheria, tetanus) separately on the nutrient media, and then killing pertussis microorganisms and anatoxins of the invention are mixed in certain proportions - obtaining heterovaccine for treating trichomonad syndrome.
    This goal is achieved in that according to the method of obtaining heterovaccine for treating Trichomonas syndrome Lactobacter1um acidophilum strains CBS 465.77, CBS 466.77, CBS 467.77, CBS 468.77, CBS 469.77, CBS 470.77, CBS 471.77. and / or CBS 472.77 is separately grown in a liquid nutrient medium under aerobic conditions, the biomass obtained is separated, inactivated, and 3-8 microorganism strains are mixed in equal amounts in physiological saline or in inverse proportions of the microorganism concentrations.
    The cultivation is carried out at a pH of 6.1-6.8 and 32-45 C.
    Inactivation is carried out with a 0.3% formaldehyde solution and a 0.5% phenol solution. . In addition, to improve the stability of heterovaccine, after mixing the microorganisms, formaldehyde, phenol or sodium mercine thiosalicylate are added.
    The strains were taken in 1976 from the vagina of women suffering from trichomonas syndrome.
    Strains introduced 10.17.77 in lyofi-. , lysed in Centreal bu reau voor Sch iramel -cultures (BaopH, the Netherlands) under the designation from CBS 465.77 to CBS 472.77 (eight separate strains),
    All eight strains are Gram-collapsing, in the form of chains or palisades.
    The strains are different in morphology and size of the colonies that form, individual colonies are very small and circular, other colonies are larger and
    have the form of a socket with grooves on the surface.
    Biochemical properties of the strains are presented in table. one.
    Table
    The strain CBS 466.77, 467.77 and 469.77 has the same biochemical and enzymatic properties. 55
    The strains are selected in such a way that when all eight strains are applied, a vaccine is obtained that is effective for each patient, by means of which, regardless of the origin of the infection, they successfully cure Trichomonas syndrome.
     For the cultivation of strains used liquid nutrient medium, the most-65
    more expedient followup composition:
    Tryptoeo-peptone, g
    Hydrolyzed
    casein, g.
    M sleep
    extract, g
    Dialysate
    yeast.vol, ml., g
    Triammonium
    citrate, g Sodium acetate, g5 Sollevar mixture, ml5, tween-80 ml1 Glucose, g10, Lactose, g10 Distilled, water, ml Up to 1000 The salt mixture consists of, g: MgSOD 7, 5 MnSO 2, 4 FeSO. . 7 HiO0.68 Distilled water, ml Up to 100, the pH of the liquid nutrient medium is adjusted to 6.1-6.8, preferably 6.5, the medium is sterilized in aktoklav at 20 minutes, then poured into Elenmeyer flasks, where samples each strain. The cultivation is carried out at, preferably, at 48 hours. After this time, the material is collected under sterile conditions and centrifuged for 1 hour at 3,000 d. The sediment formed from the biological material is transferred into suspension, preferably in physiological solution, and then Inacts are violated by treatment with formaldehyde and phenol, the preferred concentration of suspension is 0.3%, calculated on formaldehyde and 0.5%, based on f nol, with a treatment time of 3-5 days. After inactivation, the suspension is centrifuged again for 1 h at 3000 g in order to release the inactivated material from excess formaldehyde and phenol. The material obtained from each individual strain is again transferred to suspension, preferably in physiological saline, and the test for sterility and the availability of viable lactobacteria. With negative results of these tests, the density of the culture for is determined. each strain or number of microorganisms per 1 ml of culture liquid. If it is not possible to mix individual suspensions immediately after inactivation, they are stored at 4 or each strain is lyophilized and this state is stored at 4 ° C for at least 3 years. A suitable colloid for lyophilization is a suitable medium consisting of,%: gelatin 5, sucrose 37.5, and calcium lactobionate 0.5. Lyophilization was carried out for 24 hours. Inactivated material from from. individual strains are mixed in equal amounts. The resulting vaccine is worked up with a physiological solution so that it contains 14-10 microorganisms in 1 ml. The total nitrogen content of the vaccine is 3.68% dry matter. A preservative, such as formadehyde or f.enol, is added at a concentration of 0.25% or sodium ethyl mercury thiosalicylate and is left at 30 days before the vaccine can be filled with 0.5 ml ampoules. The pyrogen-free vials are filled under sterile conditions, the vials are lyophilized and stored at 4 ° C. At 2-8s, the vaccine lasts three years, at 20 ° C - 6 months. The vaccine is tested for sterility, toxicity, antigenic effect and the presence of viable lactobacilli. To test for sterility, 1 ml of the vaccine is placed in test tubes with thioglycolic culture medium and with broth — Saburo, the tubes are incubated for 10 days at 3-7 hours and corresponding to a series of treated tubes. -. Bate during the same time at. All tubes in rows were sterile. A toxicity test was performed on guinea pigs and white mice. Five guinea pigs with an average live weight of 300 g were intravenously injected with 5 ml of vaccine C (2.5 ml in each hind limb). After observing for 14 days, all animals remained healthy, no reactions were found in the treated extremities. A vaccine at a dose of 0.5 ml was administered — also to the hind limb of ten white mice with an average alive 20 g. After yablu for 14 days everyone was healthy. The antigenic test was first carried out on three guinea pigs, which, after 14 days, were administered intracardially with 5 ml of vaccine,. however, no anaphylactic reaction is observed. Then, the vaccine is tested in vitro in the reaction of nm Odterloni nanodiffusion with normal human serum, with no positive reaction.; To test for the presence of viable lactobacilli, vaccine samples are cultured on a dense nutrient medium of the following composition: Water, ml 800 Trypcasein, g 16 Solution 1, ml 50 Solution.p 2, ml 10 Solution 3, MP10 Solution 4, ml 10 Fresh yeast, g 10 Silver peptone, g ten . Soluble 0.5% starch, g 5 Water, ml Up to 1000 Solution 1 consists of a 10% solution of NaCI, solution 2 consists of a 2% solution of KC1 and 5% solution of thief, solution 3 consists of 2 % solution of 1% MgCl solution and solution 4 consists of a 2.5% solution of Kj HPOjj. To the resulting solutions add 25 g of agar-agar, bringing the pH to a value of 5.5-6.7, preferably b, and sterilized for 20 minutes in an autoclave at. Then 100 ml of an aqueous solution containing 3 g of maltose, 10 g of glucose and 10 g of lactose are added, after which 30 ml of a 1% solution of cysteine hydrochloride are added, each of these solutions being pre-sterilized through a Gj glass filter. 10% of defibrinated human blood is added to the medium. The nutrient medium is seeded with vaccine samples and the cultures are incubated at. As a control medium, Lactobactergcc asGrNiNiIT was seeded, and the culture was carried out under the same conditions. Not a single viable microorganism was detected in the vaccine. Tie. it is killed, while it has an effect against infections caused by microorganisms of the species Tg i chomonas vaginal is, i.e. from nosit.s to the class of heterovaccines. The vaccine causes the formation of specific antibodies against Lactobacter I urn acidophilum, in particular against polymorphic forms responsible for pathological changes in the pH of the vagina during the trichomonas syndrome. The immunizing effect of the vaccine has been proven in the following experiments with animals and clinical trials. Two rabbits with a live weight of 2,950 g and 3,200 g are given an intravenous infusion at 2 week intervals. Through
    sixteen
    1:10
    1:10
    1:20
    About 3 months after the second infusion, blood is taken and serum is recovered. If antibodies are formed, the serum is allowed to agglutinate at a dilution of 1:50 by the lactobacilli of the strains from which the vaccine is prepared, while the serum in the studied dilution has a positive tHT.p agglutinin. In both rabbits, the titer of agglutinin before injection was negative at a dilution of 1:10 After a month after the second infusion, the titer became positive at a dilution of 1: 160 or 1: 180. The vaccine allows therapeutic and prophylactic treatment of Trichomonas syndrome (acute, chronic and asymptomatic). For therapeutic and prophylactic treatment, a dosage of 0.5 ml (7 -ID microorganisms) is recommended intramuscularly, three times with an interval of two weeks, followed by the introduction of the same dose with Runnel injection one year after the start of treatment. Clinical studies were carried out on 97 patients who were subjected to serological tests. Patients were sampled according to a time schedule and the resulting KPVI serum was tested for the presence of lactobacterial antibodies. For this, serum in increasing dilution (Cell 1:10 to 1: 1280) is treated with a vaccine from the corresponding antigens or agglutinins and the resulting agglutination is observed. As agglutinins, a freshly prepared suspension of inactivated LactobacteriUrn acfdophilum microorganisms of the same strains in the same weight ratio and, the same concentration is used (14-10 microorganisms per 1 ml of the vaccine itself. The appearance of agglutinin in serum and the growth of its titers is shown in Table 2. Table 2 Considering the increase in the titer of agglutinin 40 during the period between the first and the second Increase of the titer 2X Number of patients 13 Share of patients from total 13, 4 21.6%,% 13.4
    Prime P 200 women aged 15-59 years suffering from Trichomonas syndrome were treated on an outpatient basis with a vaccine made from 8 strains. The control was carried out for 2 years. 138 patients (69% of the total X-ray count) were previously unsuccessfully treated with metronidazole. Before starting treatment along with the study
    : Continued table. 2
    Blood and urine. A gynecological examination was performed, including colposcopy and Pap-Smear,
    concurrently, swabs from the vagina, vulva, cervix, and urechra were taken to prepare native preparations and preparations stained with. Gram and Gimzu. The culture was applied to Trichomonas vagi nails. With blood collection, the patients can be distributed as indicated in table. 3. Table 3 64X and more 7 10.3 6.2
    Doppings were repeated after weeks, 4 and 12 months after the start of treatment.
    Before starting treatment in 145 patients (172.5%), severe symptoms of trichomonas syndrome with severe colpitis, pruritus with abundant green-yellowish, foul-smelling white bladder, dyspareunia and dysygia were found, edema and erythema and heart volume, in the case of a colposcopy, edema and part of the rectal and adrenaliomyopathy and dysygia were detected, during the colposcopy, the edema and the part of the rectum and the numberal part of the part of the rectal and the prostomy, the part of the rectal, and the nodule and the part of the rectal, and the normal part of the rectal, and the normal part of the rectal and the rectal part of the rectal part of the rectal and adrenaline and dysygia was detected; . In addition, 61 patients had erythroplasty of the vaginal part of the cervix, and 13 had chronic cervicitis. In the remaining 55 patients, a C (27/5%) patient, only mild colpitis was detected.
    The treatment was carried out according to the above dosage. In cases of legacy
    200 vaccinations
    139
    200 (69.5%)
    164
    198 С82%
    157
    198 (79.3%;
     Nine patients who had a microscopic Trichomonas vaginal is microscopically determined at the second control (three months after vaccination) remained immune to further treatment, and oral administration of trichomonacide also did not change anything.
    After 12 months, there were also changes in the cervix in the form of chronic cervicitis or significant erythroplasty, which is explained by the fact that
    iKoro colpitis did not use additional therapy / for acute symptoms: antibiotics were prescribed, and in severe conditions, an additional local application of the drug from Lactobacterturn acldophllum strains that are effective against MonIIt a s s. Metronidazole or similar nitroimidazole derivatives were not prescribed in any case. If the vaginal discharge is classified by ifirovec, then the success of the treatment can be traced using the Table. 4, where class I means absence of disease, class II -, lung bacterial leucorrhoea, class III - purulent bacterial leucorrhoea, class. IV - gonor (such cases have not been studied; class V - trichomonads (positive native drug), class VI - Mycosis of the vagina (Candida alb Jeans).
    ; Table 4
    6
    194 C3% j
    (97%;
    14
    47
    (7%; (23.5%;
    27
    (4.5%; (13.5%)
    9
    32 (16.2%)
    (4.5%;
    权利要求:
    Claims (4)
    [1]
    Womens are able to form antytel. 198 (95.5% of patients undergoing treatment were cured of trichomonoea after 12 months (before treatment they had vaginal leucorrhea in class II and III). The same result was obtained in 55 patients with mild colpitis without additional therapy. after two years, they were again observed, during which time no cases of reinfection were detected.All during and after treatment, no allergic and toxic reactions were identified, however, 3 cases of acute febrile infections, diseases of the system should be refrained from vaccination. g emathopoiesis or severe renal failure. Claim 1. Method for preparing heterovaccine for treating trichrmonad syndrome 3 and with FTOM, that Lactobacterlura acldophllum strain CBS 465.77, CBS 466.77, CBS467.7 CBS 468.77, CBS 469.77, CBS 470.77 / CBS 471.77 and / or CBS 472.77 are individually grown by IB at a discount on the nutrient medium ri.-aerobic conditions, the resulting biomass is separated, lactated, and 3-8 strains of microorganisms are mixed in equal quantities in physiological solution or in volumes inversely proportional to microbial concentrations.
    [2]
    2. The method according to claim 1, wherein the cultivation is carried out at a pH of 6.1-6.8 and 3245 ° C.
    [3]
    3. The method according to claim 1, about tl and h a-s s and y and the fact that the inactivation is carried out with a 0.3% formaldehyde solution and 0-5% phenol solution.
    [4]
    4. The method according to claim 1, in connection with the fact that, in order to increase the stability of heterovaccine, after mixing the microorganisms. formaldehyde, phenol, or sodium ethyl mercury thio-sulphate are added. Sources of information taken into account in the examination 1. MRTU-42 263-68 at the DTP vakinu.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU997599A3|1983-02-15|Process for preparing heterovaccine for treating trichomonas syndrome
    Adlam et al.1976|Natural and experimental staphylococcal mastitis in rabbits
    US4472378A|1984-09-18|Live vaccine for the prevention of salmonellosis in water fowl, a process for making and applying the same
    Dack et al.1937|Further studies on Bacterium necrophorum isolated from cases of chronic ulcerative colitis
    US4229434A|1980-10-21|Vaccine for prophylaxis of trichophytosis in horse and method of preparing same
    US3470294A|1969-09-30|Vaccine for immunization of dogs and foxes against distemper,hepatitis contagiosa and leptospirosis and process for preparing it
    US4386065A|1983-05-31|Vaccine against EAE
    RU2425148C2|2011-07-27|Brucella abortus uf-1 strain for preparing biological preparations for diagnostics and specific prevention of brucellosis in farm animals
    US3098011A|1963-07-16|Process of producing a vaccine against distemper
    RU2432174C1|2011-10-27|Method for producing colibacillosis anatoxin
    US5198214A|1993-03-30|Anti-mastitis polyvalent vaccine, method of administration and method for production thereof
    US4312947A|1982-01-26|Process for the preparation of a vaccine against panleucopenia of the cat
    US4762712A|1988-08-09|Anti-mastitis polyvalent vaccine, method of administration and method for production thereof
    EA029938B1|2018-05-31|Vaccine against strangles in horses
    RU2521651C1|2014-07-10|STRAINS OF BACTERIA Moraxella bovoculi "SH-CH6 N-DEP" USED TO MANUFACTURE DIAGNOSTIC PREPARATIONS AND VACCINES AGAINST INFECTIOUS KERATOCONJUNCTIVITIS OF CATTLE
    Findlay1946|Pleuropneumonia-like organisms and arthritis
    US3836648A|1974-09-17|Treatment of canine distemper with a microbial product derived from the bacterium achromobacter stenohalis
    RU2429880C1|2011-09-27|Method to manufacture vaccine associated against streptococcosis and virus haemorrhagic disease of rabbits
    Jansson et al.1971|Search for mycoplasma in rheumatoid arthritis.
    RU2406531C1|2010-12-20|Associated vaccine against streptoccocosis, pseudomonosis and enterococcus infection in nutria
    RU2145353C1|2000-02-10|Strain of bacterium moraxella bovis "g97-vnivi" used for preparing diagnostica and vaccines against infectious keratoconjunctivitis in cattle
    RU2162340C1|2001-01-27|Method of preparing vaccine against salmonellosis in pigs
    RU2098127C1|1997-12-10|Mixed vaccine for control over cattle necrobacteriosis
    RU2366455C2|2009-09-10|Method for preparing specific immunomodulator
    RU2147892C1|2000-04-27|Method of preparing preparation based on virus-bacterial strains from local focus for preparing mixed vaccine or polyvalent hyperimmune serum against cattle disease
    同族专利:
    公开号 | 公开日
    DD141163A5|1980-04-16|
    SE7813201L|1979-06-24|
    YU303078A|1983-06-30|
    SE431400B|1984-02-06|
    DK152174C|1988-06-20|
    ATA883578A|1982-02-15|
    GB2010677A|1979-07-04|
    FR2412314B1|1982-07-02|
    FR2412314A1|1979-07-20|
    US4238478A|1980-12-09|
    AT368390B|1982-10-11|
    ES476703A1|1979-12-01|
    CA1119095A|1982-03-02|
    PL211979A1|1980-02-25|
    MX5876E|1984-08-16|
    FI65166C|1984-04-10|
    JPS54140716A|1979-11-01|
    FI783946A|1979-06-24|
    FI65166B|1983-12-30|
    IL56177D0|1979-03-12|
    PL117618B1|1981-08-31|
    AU521538B2|1982-04-08|
    IL56177A|1981-12-31|
    DK562178A|1979-06-24|
    NO149316C|1984-03-28|
    ZA786978B|1979-11-28|
    DK152174B|1988-02-08|
    JPS6231693B2|1987-07-09|
    YU42170B|1988-06-30|
    IT7869945D0|1978-12-22|
    IN150348B|1982-09-18|
    EG14095A|1983-03-31|
    DE2854723A1|1979-06-28|
    NO784306L|1979-06-26|
    DE2854723B2|1981-02-12|
    IT1109099B|1985-12-16|
    KR820000045B1|1982-02-06|
    AR220548A1|1980-11-14|
    AU4292778A|1979-06-28|
    CH639280A5|1983-11-15|
    NL179543C|1986-10-01|
    BE872884A|1979-06-19|
    GR65648B|1980-10-15|
    DE2854723C3|1982-03-25|
    GB2010677B|1982-06-16|
    NO149316B|1983-12-19|
    PH16435A|1983-10-07|
    NL7812295A|1979-06-26|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    GB190925675A|1908-11-07|1910-02-17|August Wassermann|Substances Serving for the Local Immunisation of Diseased Tissues, and Methods of Preparing same.|
    FR2946M|1963-08-27|1964-12-24|Salvoxyl Lab|Medicinal product of biological origin, in particular for the reconstitution of the intestinal flora.|
    FR6836M|1967-11-29|1969-03-31|
    DK127268A|1970-01-12|1900-01-01|
    US3957974A|1974-11-05|1976-05-18|Seikenkai|Method for deodorization of excrements|
    JPS5218879A|1975-06-24|1977-02-12|Seikenkai|Method for culturing a stool deodorant germ belonging to lactobacillus genus|
    JPS6234731B2|1976-02-23|1987-07-28|Seikenkai|
    JPS52154590A|1976-05-21|1977-12-22|Seikenkai|Cultivating and preserving method of deodorising lactobucillus and liling cell preparation|
    EP1562168A3|2004-02-03|2006-07-19|Lg Electronics Inc.|Electro-luminescence display device and driving method thereof|IE59079B1|1986-11-05|1994-01-12|Oldcastle Veterinary Research|A method of preparing an autogenous vaccine|
    US5549899A|1992-12-04|1996-08-27|University Technologies International, Inc.|Giardia vaccine|
    US5512288A|1992-12-04|1996-04-30|University Technologies International, Inc.|Giardia vaccine|
    AU6244094A|1993-02-24|1994-09-14|Sherwood L. Gorbach|Method of enhancing immune response to oral vaccines|
    HU227086B1|1999-11-25|2010-06-28|Vakcina Kft|Lactobacillus vaccine for treating prostata inflammatory and benign prostata hyperplasia|
    DE102004046391A1|2004-09-24|2006-04-06|Bioveta Ag|New vaccine for veterinary and human medical prophylaxis and therapy|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    CH1601277A|CH639280A5|1977-12-23|1977-12-23|METHOD FOR PRODUCING A VACCINE AGAINST TRICHOMONAS SYNDROME.|
    [返回顶部]